In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4652-4658

  Miyazaki, Mamiko ^a   Horii, Takaaki ^a   Hata, Katsura ^a   Watanabe, Nao Aki ^a   Nakamoto, Kazutaka ^a   Tanaka, Keigo ^a   Shirotori, Syuji ^a   Murai, Norio ^a   Inoue, Satoshi ^a   Matsukura, Masayuki ^a   Abe, Shinya ^a   Yoshimatsu, Kentaro ^a   Asada, Makoto ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; E1210; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CELL COUNT; CLINICAL ASSESSMENT; CYTOTOXICITY; DRUG SYNTHESIS; FUNGAL STRAIN; FUNGUS ISOLATION; FUSARIUM SOLANI; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; PAECILOMYCES; PAECILOMYCES LILACINUS; PETRIELLIDIUM BOYDII; PRIORITY JOURNAL; SCEDOSPORIUM; YEAST;

AMINOPYRIDINES; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; CELL LINE; ECHINOCANDINS; FLUCONAZOLE; FUNGI; FUSARIUM; HUMANS; ISOXAZOLES; ITRACONAZOLE; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PAECILOMYCES; PSEUDALLESCHERIA; PYRIMIDINES; SCEDOSPORIUM; TRIAZOLES; YEASTS;

EID: 80052854203     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00291-11     Document Type: Article

References (28)

1. Bates, D. W., et al. 2001. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32:686-693.
2. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. CLSI document M27-A3. CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: approved standard, 2nd ed. CLSI document M38-A2. CLSI, Wayne, PA.
4. Cortez, K. J., et al. 2008. Infections caused by Scedosporium spp. Clin. Microbiol. Rev. 2008 21:157-197.
5. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. (Pubitemid 37222342)
6. Enoch, D. A., H. A. Ludlam, and N. M. Brown. 2006. Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol. 55:809-818.
7. Hata, K., T. Horii, M. Miyazaki, and N. Watanabe. 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-842.
8. Hatano, K., Y. Morishita, T. Nakai, and F. Ikeda. 2002. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J. Antibiot. (Tokyo) 55:219-222. (Pubitemid 34285463)
9. Horii, T., M. Okubo, M. Miyazaki, K. Hata, and N. Watanabe. 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-843.
10. Lass-Flörl, C., et al. 2005. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br. J. Haematol. 131: 201-207.
11. Nakamoto, K., et al. 2010. Synthesis and evaluation of novel antifungal agents - quinoline and pyridine amide derivatives. Bioorg. Med. Chem. Lett. 20:4624-4626.
12. Neofytos, D., et al. 2009. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48:265-273.
13. Nucci, M., and E. Anaissie. 2007. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 20:695-704.
14. Oakley, K. L., C. B. Moore, and D. W. Denning. 1998. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. 42:2726-2730.
15. Okubo, M., N. Toritsuka, T. Horii, K. Hata, and J. Sonoda. 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-844.
16. Ostrosky-Zeichner, L., et al. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
17. Pastor, F. J., and J. Guarro. 2006. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin. Microbiol. Infect. 12:948-960.
18. Pfaller, M. A., and D. J. Diekema. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
19. Rennie, R., C. Sand, and R. Sherburne. 1997. Electron microscopic evidence of the effect of LY303366 on Aspergillus fumigatus. Abstr. 13th Congr. Int. Soc. Hum. Animal Mycol., abstr. P451.
20. Richard, M. L., and A. Plaine. 2007. Comprehensive analysis of glycosylphosphatidylinositol- anchored proteins in Candida albicans. Eukaryot. Cell 6:119-133.
21. Rincón, S., M. C. Cepero de García, and A. Espinel-Ingroff. 2006. A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole. J. Clin. Microbiol. 44:3429-3431.
22. Roden, M. M., et al. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653.
23. 2: synthesis of a (2-aminopyridin-3- yl)isoxazole derivative and its antifungal activity. Chem. Lett. 39:1033-1035.
24. Tawara, S., et al. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44:57-62.
25. Tsukahara, K., et al. 2003. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol. Microbiol. 48:1029-1042.
26. Umemura, M., et al. 2003. GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast. J. Biol. Chem. 278:23639-23647.
27. Velegraki, A., E. C. Alexopoulos, S. Kritikou, and G. Gaitanis. 2004. Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest. J. Clin. Microbiol. 42:3589-3593.
28. Watanabe, N., M. Miyazaki, T. Horii, and K. Hata. 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-841.